Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
CHRS
#3090
Coherus Oncology, Inc. Common Stock
1.740
0
USD
+2.96%
Sektör:
Sağlık hizmetleri
Baz:
USD
Kar para birimi:
USD
Günlük aralık
Yıllık aralık
Günlük değişim
+2.96%
Aylık değişim
+9.43%
6 aylık değişim
+8.07%
Yıllık değişim
+8.07%
Önceki kapanış
1.690
0
Open
1.740
0
Bid
Ask
Low
1.740
0
High
1.740
0
Hacim
40
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
CHRS
Open full chart
Financials
Overview
Rapor
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
72.79 M
77.28 M
79.61 M
112.71 M
115.9 M
149.89 M
—
Valuation ratios
Enterprise value
724 M
816.12 M
613.93 M
251.03 M
33.95 M
123.96 M
98.09 M
Price to earnings ratio
10.73
-4.19
-2.26
-1.24
5.52
0.99
2.02
Price to sales ratio
3.05
3.69
3.13
1.15
0.59
3.94
5.11
Price to cash flow ratio
9.41
32.17
2.74
1.69
7.75
1.2
-104.51
Price to book ratio
5.16
12.32
4.81
1.53
1.2
2.73
3.44
Enterprise value to EBITDA ratio
1.83
3.91
6.83
5.75
0.28
57.18
58.84
Profitability ratios
Return on assets %
0.16
0.42
0.61
0.38
0.06
0.65
0.04
Return on equity %
0.47
2.94
2.12
1.23
0.22
2.75
-0.44
Return on invested capital %
270.47
458.6
483.09
271.04
182.25
313.07
—
Gross margin %
92.08
82.36
66.79
38.19
55.97
67.24
268.09
Operating margin %
32.85
80.8
121.72
78.99
41.83
429.51
1 784.54
EBITDA margin %
83.35
63.87
42.6
16.97
44.9
5.14
-1 810.45
Net margin %
27.79
87.92
138.24
92.48
10.68
398.43
2 215.19
Liquidity ratios
Quick ratio
4.97
3.42
2.47
1.24
0.96
1.45
5.31
Current ratio
5.27
3.64
2.75
1.43
1.21
1.47
5.37
Inventory turnover
1.39
1.41
1.83
3.14
1.77
0.38
3.6
Asset turnover
0.76
0.43
0.36
0.46
0.5
0.12
0.1
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.45
0.56
0.47
0.36
0.51
—
—
Long term debt to total equity ratio
1.34
3.9
1.64
1.17
1.73
—
—
Per share metrics
Operating cash flow per share
1.85
0.5
3.11
1.86
0.18
1.18
1.19
EBIT per share
4.71
2.72
1.06
0.43
1.03
0.01
-1.59
EBITDA per share
4.75
2.76
1.16
0.46
1.04
0.02
-1.58
Total debt per share
—
—
—
—
—
—
—
Cash per share
6.48
5.53
2.47
1.25
1.1
1.47
5.88
Net current asset value per share
9.19
7.98
4.91
5.05
2.97
1.76
11.68
Tangible book value per share
3.32
1.25
1.68
1.29
0.68
0.13
2.16
Working capital per share
7.45
5.79
3.12
1.53
0.51
0.57
2.81
Book value per share
3.37
1.3
1.77
2.05
1.15
0.52
3.89
Haberler
Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?
Coherus BioSciences Citizens Konferansı’nda: Stratejik Onkoloji Dönüşümü
Coherus BioSciences at The Citizens Conference: Strategic Oncology Shift
Oppenheimer, Coherus Biosciences için Outperform notunu tekrarladı
Oppenheimer reiterates Coherus Biosciences stock rating at Outperform
Coherus Oncology, Inc. (CHRS) Q4 2025 Earnings Call Transcript
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Coherus BioSciences kazancı beklentilere uygun, kâr ise beklentilere göre düşük
Coherus BioSciences earnings matched, revenue fell short of estimates
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Beats Revenue Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) Misses Q4 Earnings Estimates
Myriad Genetics (MYGN) Q4 Earnings and Revenues Surpass Estimates